Atomo Diagnostics (ASX:AT1)
is pleased to announce it has expanded its existing Covid-19 rapid test partnership with Access Bio LLC.
Atomo will now have non-exclusive rights to market and distribute Access’ Covid-19 rapid antigen test in Australia, New Zealand and India.
It’s set to be called the Atomo Covid-19 Antigen Test.
It is a nasopharyngeal swab test designed to screen for antigens produced in response to Covid-19 infections.
Unlike the general nasal swab testing in Australia which must go to a central laboratory for processing, the Atomo Covid-19 Antigen Test is processed at the point of care and results are available after 10 minutes.
Shares in Atomo Diagnostics (ASX:AT1)
are trading 1.4 per cent higher at 37 cents.